Stockscreener 앱 받기
12.70
3.42%
-0.45
시간 외 거래:
12.70
전일 마감가:
$13.15
열려 있는:
$13.34
하루 거래량:
120.41K
Relative Volume:
0.70
시가총액:
$435.92M
수익:
$99.53M
순이익/손실:
$-21.57M
주가수익비율:
-19.57
EPS:
-0.6488
순현금흐름:
$-9.84M
1주 성능:
-9.67%
1개월 성능:
-16.39%
6개월 성능:
-13.31%
1년 성능:
+21.76%
1일 변동 폭
$12.68
$13.34
1주일 범위
$12.68
$14.45
52주 변동 폭
$9.22
$19.60
뉴로페이스 Stock (NPCE) Company Profile
명칭
Neuropace Inc
전화
(650) 237-2700
주소
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
12.70 | 482.60M | 99.53M | -21.57M | -9.84M | -0.6488 |
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
뉴로페이스 Stock (NPCE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-03-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 개시 | Leerink Partners | Outperform |
| 2023-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-24 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 개시 | Lake Street | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 개시 | Robert W. Baird | Outperform |
| 2021-05-17 | 개시 | JP Morgan | Overweight |
| 2021-05-17 | 개시 | Morgan Stanley | Overweight |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 개시 | Wells Fargo | Overweight |
모두보기
뉴로페이스 주식(NPCE)의 최신 뉴스
Neuropace Stock Price Forecast. Should You Buy NPCE? - StockInvest.us
After shares were withheld for taxes, NeuroPace (NPCE) medical chief Martha Morrell held 51,357 shares. - Stock Titan
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
(NPCE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Form 4 Neuropace Inc For: 22 September By Investing.com - Investing.com Canada
NeuroPace CFO Patrick Williams Discloses Tax-Related Share Withholding on RSU Vesting - Kalkine Media
NeuroPace (NPCE) CFO has 1,162 shares withheld for taxes - Stock Titan
NeuroPace (NASDAQ:NPCE) Upgraded to "Strong-Buy" at KeyCorp - MarketBeat
NEUROPACE, INC. : KEYBANC INITIATES COVERAGE WITH OVERWEIGHT RATING AND TARGET PRICE $18 - Bitget
Keybanc initiates coverage of NeuroPace with Overweight rating, $18 price target - TradingView
Neuropace, Inc. (NPCE) Stock Analysis: 43% Potential Upside With Strong Buy Ratings - DirectorsTalk Interviews
KeyBanc initiates NeuroPace stock coverage with overweight rating By Investing.com - Investing.com Australia
KeyBanc initiates NeuroPace stock coverage with overweight rating - Investing.com
KeyBanc Initiates NeuroPace(NPCE.US) With Buy Rating, Announces Target Price $18 - Moomoo
Cantor Fitzgerald reiterates Overweight on NeuroPace stock at $21 By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight on NeuroPace stock at $21 - Investing.com
Precision Trading with Neuropace Inc. (NPCE) Risk Zones - Stock Traders Daily
Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCE - MarketBeat
First Light Asset Management, LLC Adds 1.34 Million NeuroPace In - GuruFocus
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report? - Yahoo Finance
First Light Asset Management LLC Boosts Stake in NeuroPace, Inc. $NPCE - MarketBeat
NeuroPace Inc. (NPCE) Eases 1.76% to $14.50 as Shares Sit Mid-Range Between Support and ResistanceVolume Gap - siam.in
Neuropace Inc (NASDAQ: NPCE) Share Price, NPCE Stock News, NPCE Share Price & Updates - Kalkine
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com India
NeuroPace at Wells Fargo conference: IGE push faces FDA test By Investing.com - Investing.com Canada
NPCE: Strong clinical data and regulatory progress position the RNS system for significant growth in epilepsy care - tradingview.com
NeuroPace at Wells Fargo conference: IGE push faces FDA test - Investing.com
NeuroPace (NPCE) CEO uses 1,310 shares to cover taxes - Stock Titan
Over 12% of NeuroPace (NPCE) may be owned by one investor - Stock Titan
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now - Yahoo Finance
Man Group plc Makes New $1.34 Million Investment in NeuroPace, Inc. $NPCE - MarketBeat
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc. - MarketBeat
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - Investing News Network
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference - Business Wire
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace (NPCE) CEO settles RSU tax bill with 1,126 shares - Stock Titan
NeuroPace (NASDAQ: NPCE) CMO has 358 shares withheld for taxes - Stock Titan
NeuroPace Inc (NPCE) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Neuropace (NPCE) Results Check: EPS Lands Above Forecast; Share Move: Shares Finish 1.22% Up on the DayEarnings Call Transcript - careplusvn.com
Deutsche Bank AG Acquires Shares of 938,919 NeuroPace, Inc. $NPCE - MarketBeat
Neuropace (NPCE) Stock: Ends Up by 0.07% at $14.03; Technical Setup: the $13.33 to $14.73 Range Remains in Focus at the CloseMFI Oversold - vinanet.vn
Neuropace (NPCE) Market: Posts a 0.07% Gain to $14.03 in the Current Update; Technical View: the $13.33 to $14.73 Range Remains in Focus in Latest TradingPassive Flow - vinanet.vn
HC Wainwright Has Positive Outlook of NeuroPace Q3 Earnings - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for NeuroPace - MarketBeat
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayTrend Following Picks - vinanet.vn
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ... By GuruFocus - Investing.com Canada
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? - Yahoo Finance
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - Yahoo Finance
뉴로페이스 (NPCE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.26%
0.38%
자본화:
|
볼륨(24시간):